

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)
AVATROBOPAG FOR TREATING PRIMARY CHRONIC IMMUNE THROMBOCYTOPENIA
(NICE TA 853)

RED - RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALIST ONLY.
NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.

Name: generic (trade)	What it is	Indication	Date decision last revised	Decision status	NICE / SMC Guidance
Avatrombopag (Doptelet®)	Thrombopoietin (TPO) receptor agonist	Avatrombopag is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	February 2023	Final	NICE TA - 853 recommended

HWE APC recommendation:

Avatrombopag is recommended, within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (for example, corticosteroids, immunoglobulins) in adults in line with the recommendations in [NICE TA 853](#) and initiation criteria for TPO-RAs already agreed across HWE ICB:

- diagnosis of ITP >12 months duration and
- standard active therapies (including rituximab and immunosuppressants e.g. azathioprine, ciclosporin, mycophenolate) have failed to control bleeding requiring hospitalisation, or where patient is intolerant of these therapies
- platelet count <30x10⁹/L and requiring rescue treatments with IVIg

Discontinue if platelet count does not increase to ≥ 50 x 10⁹/L after 4 weeks at maximum dose of 40 mg once daily. Discontinue if platelet count is greater than 250 x 10⁹/L after 2 weeks of dosing at 20 mg once weekly. Red status (specialist prescribing/monitoring).

National tariff excluded.

If avatrombopag is considered one of a number of suitable treatments, the least expensive (taking into account administration costs & patient access schemes) should be chosen.

RED STATUS:

- **NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.**
- **RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALISTS**

NICE TA 853 recommendations:

Avatrombopag is recommended, within its marketing authorisation, as an option for treating primary chronic immune thrombocytopenia (ITP) refractory to other treatments (for example, corticosteroids, immunoglobulins) in adults. It is only recommended if the company provides it according to the commercial arrangement.